Healthcare of Ontario Pension Plan Trust Fund Invests $26.35 Million in Urogen Pharma $URGN

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Urogen Pharma (NASDAQ:URGN) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 1,125,100 shares of the company’s stock, valued at approximately $26,350,000. Healthcare of Ontario Pension Plan Trust Fund owned about 2.40% of Urogen Pharma at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Barclays PLC lifted its position in shares of Urogen Pharma by 3.8% during the 4th quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after purchasing an additional 2,125 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Urogen Pharma by 55.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 55,686 shares of the company’s stock worth $1,293,000 after purchasing an additional 19,749 shares during the last quarter. Morgan Stanley lifted its position in shares of Urogen Pharma by 1.4% during the 4th quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock worth $60,023,000 after purchasing an additional 34,455 shares during the last quarter. Informed Momentum Co LLC purchased a new stake in shares of Urogen Pharma during the 4th quarter worth $3,757,000. Finally, New York State Common Retirement Fund lifted its position in shares of Urogen Pharma by 62.5% during the 4th quarter. New York State Common Retirement Fund now owns 12,737 shares of the company’s stock worth $298,000 after purchasing an additional 4,900 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 5,222 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $27.30, for a total value of $142,560.60. Following the completion of the sale, the insider directly owned 139,763 shares of the company’s stock, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.80% of the company’s stock.

Urogen Pharma Price Performance

Shares of URGN opened at $30.86 on Tuesday. Urogen Pharma has a 1-year low of $12.61 and a 1-year high of $32.37. The stock has a market cap of $1.50 billion, a PE ratio of -11.22 and a beta of 1.59. The firm has a fifty day moving average price of $25.96 and a 200 day moving average price of $22.86.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to analysts’ expectations of $44.83 million. As a group, equities analysts expect that Urogen Pharma will post -0.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

URGN has been the subject of several recent analyst reports. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price objective for the company. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. D. Boral Capital reissued a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a research report on Tuesday, March 31st. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.